The epidemiology of inflammatory bowel disease: Clues to pathogenesis?
- PMID: 36733765
- PMCID: PMC9886670
- DOI: 10.3389/fped.2022.1103713
The epidemiology of inflammatory bowel disease: Clues to pathogenesis?
Abstract
Historically, inflammatory bowel disease (IBD) was most common in North America and Europe and more common with a north-south gradient. Over the past century, there has been a marked increase in IBD in general and in childhood IBD in particular and over the past 50 years IBD has spread into the developing world. The greatest risk factor of developing IBD is an affected family member. Concordance rates between dizygotic twins is ∼4% and ∼50% in monozygotic twins, and more than half of pairs are diagnosed within 2 years of each other. Nevertheless, most patients with IBD do not have an affected family member. More than 200 genes are associated with an increased risk for IBD, but most associations are weak with odds ratios between 1.2 and 2.0 suggesting the environment plays a role. IBD is more common in urban than rural regions and is associated with "good standards" of domestic hygiene during childhood. People who migrate from areas with a low incidence to areas with a high incidence of IBD have an increased risk of developing IBD and the younger they are when they migrate, the greater their risk of developing IBD. Moreover, people who migrate from regions with a high incidence to areas with a low incidence of IBD have a decreased risk of developing IBD. Together, these findings strongly suggest particular environmental exposures occurring early in life may trigger inflammatory bowel disease in genetically susceptible individuals. The key is figuring out what those exposures might be.
Keywords: Crohn's disease; environment; epidemiology; etiology; genetics; inflammatory bowel disease; pathogenesis; ulcerative colitis.
© 2023 Borowitz.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Epidemiology.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S6-S16. doi: 10.1093/jcag/gwy054. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294381 Free PMC article.
-
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2. J Can Assoc Gastroenterol. 2019. PMID: 31294385 Free PMC article.
-
Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study.Inflamm Bowel Dis. 2008 Jul;14(7):968-76. doi: 10.1002/ibd.20380. Inflamm Bowel Dis. 2008. PMID: 18253950
-
The epidemiology and the pathogenesis of inflammatory bowel disease.Eur J Radiol. 2000 Sep;35(3):154-67. doi: 10.1016/s0720-048x(00)00238-2. Eur J Radiol. 2000. PMID: 11000558 Review.
-
Epidemiology of inflammatory bowel disease.Med Clin North Am. 1990 Jan;74(1):1-12. doi: 10.1016/s0025-7125(16)30581-8. Med Clin North Am. 1990. PMID: 2404170 Review.
Cited by
-
Marine Algae and Deriving Biomolecules for the Management of Inflammatory Bowel Diseases: Potential Clinical Therapeutics to Decrease Gut Inflammatory and Oxidative Stress Markers?Mar Drugs. 2024 Jul 25;22(8):336. doi: 10.3390/md22080336. Mar Drugs. 2024. PMID: 39195452 Free PMC article. Review.
-
A Comprehensive Exploration of Therapeutic Strategies in Inflammatory Bowel Diseases: Insights from Human and Animal Studies.Biomedicines. 2024 Mar 26;12(4):735. doi: 10.3390/biomedicines12040735. Biomedicines. 2024. PMID: 38672091 Free PMC article. Review.
-
Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date.Int J Mol Sci. 2025 Jan 6;26(1):413. doi: 10.3390/ijms26010413. Int J Mol Sci. 2025. PMID: 39796266 Free PMC article. Review.
-
Bone marrow mesenchymal stem cell-derived exosomes alleviate DSS-induced inflammatory bowel disease in mice through inhibiting intestinal epithelial cell pyroptosis via delivery of TSG-6.Front Immunol. 2025 Jun 30;16:1601591. doi: 10.3389/fimmu.2025.1601591. eCollection 2025. Front Immunol. 2025. PMID: 40661945 Free PMC article.
-
CRIF1 gene therapy ameliorates inflammatory bowel disease by suppressing TH17 cells and fibrosis through mitochondrial function regulation.Front Immunol. 2025 Jul 31;16:1618012. doi: 10.3389/fimmu.2025.1618012. eCollection 2025. Front Immunol. 2025. PMID: 40821844 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous